Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States.
The last earnings update was 43 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Neon Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Neon Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Neon Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Neon Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Neon Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Neon Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Neon Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Neon Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Neon Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Neon Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Hugh O’Dowd, M.B.A. has been Chief Executive Officer and President of Neon Therapeutics Inc. since September 27, 2016. Mr. O’Dowd joined Neon Therapeutics from Novartis, where he spent more than 20 years in a variety of leadership roles, including Chief Commercial Officer and Head of Global Strategy of Novartis Oncology. In this role, he was responsible for global commercialization for the oncology portfolio, including Global Brand Leadership, Health Economics & Pricing, Early Phase Commercial Development, Strategic Capabilities, Business Development & Licensing and Global Sales Excellence. He has great depth of expertise in oncology, and has played a pivotal role in building Novartis Oncology into one of the world’s leading oncology companies. He has deep experience in pharmaceutical leadership, moving important oncology therapies from clinical development through commercialization. He began his career in pharmaceuticals in 1992 at Glaxo in sales, and moved to Novartis in 1996. Following a career of increasing levels of responsibility in sales and marketing, he took a leading role in the commercialization of Gleevec, and assumed country- and region-level commercial leadership roles before overseeing the entirety of Novartis Oncology commercialization and strategy in 2011. Since 2015, Mr. O’Dowd was Country President and General Manager in the United Kingdom and Ireland. He has been a Director at Neon Therapeutics Inc since October 3, 2016. Mr. O’Dowd holds a B.A. from Loyola University Chicago, and an MBA from the Kellstadt Graduate School of Business at DePaul University Chicago.
Insufficient data for Hugh to compare compensation growth.
Hugh's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Neon Therapeutics management team is about average.
Founder & Director
Chief Financial Officer
President of Research & Development
Founder & CTO
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Neon Therapeutics board of directors is about average.
Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.